Shares of Boston Scientific Corporation (NYSE:BSX) have been given an average recommendation of “Buy” by the twenty-one research firms that are presently covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $30.91.

Several equities research analysts recently issued reports on BSX shares. BMO Capital Markets lifted their price objective on Boston Scientific from $30.00 to $32.00 and gave the stock an “outperform” rating in a report on Friday, October 27th. Stifel Nicolaus reiterated a “buy” rating and issued a $32.00 price objective on shares of Boston Scientific in a report on Monday, September 25th. SunTrust Banks set a $33.00 price objective on Boston Scientific and gave the stock a “buy” rating in a report on Monday, December 4th. Zacks Investment Research upgraded Boston Scientific from a “sell” rating to a “buy” rating and set a $33.00 price objective on the stock in a report on Friday, October 20th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $32.00 price objective on shares of Boston Scientific in a report on Tuesday, October 3rd.

Boston Scientific (NYSE BSX) traded up $0.15 during trading hours on Friday, hitting $27.40. The stock had a trading volume of 6,942,000 shares, compared to its average volume of 10,931,941. The company has a debt-to-equity ratio of 0.58, a current ratio of 0.72 and a quick ratio of 0.50. Boston Scientific has a 52-week low of $23.29 and a 52-week high of $29.93. The firm has a market cap of $37,419.59, a PE ratio of 44.92, a PEG ratio of 1.95 and a beta of 0.96.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Thursday, October 26th. The medical equipment provider reported $0.31 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.31. Boston Scientific had a return on equity of 23.60% and a net margin of 9.55%. The company had revenue of $2.22 billion for the quarter, compared to analysts’ expectations of $2.21 billion. During the same period in the previous year, the firm posted $0.27 EPS. Boston Scientific’s revenue was up 5.6% compared to the same quarter last year. equities research analysts expect that Boston Scientific will post 1.25 earnings per share for the current year.

In other news, insider Valley Gold Master Fund L. Sun purchased 408,006 shares of Boston Scientific stock in a transaction dated Tuesday, November 28th. The shares were purchased at an average price of $0.45 per share, with a total value of $183,602.70. Also, SVP David A. Pierce sold 5,152 shares of Boston Scientific stock in a transaction that occurred on Tuesday, January 9th. The shares were sold at an average price of $27.00, for a total transaction of $139,104.00. Following the sale, the senior vice president now directly owns 38,116 shares in the company, valued at approximately $1,029,132. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 96,585 shares of company stock worth $2,578,197. Insiders own 0.74% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the company. Valeo Financial Advisors LLC purchased a new stake in shares of Boston Scientific during the 3rd quarter valued at approximately $138,000. Steward Partners Investment Advisory LLC purchased a new stake in shares of Boston Scientific during the 3rd quarter valued at approximately $139,000. San Francisco Sentry Investment Group CA purchased a new stake in shares of Boston Scientific during the 2nd quarter valued at approximately $191,000. Ironwood Investment Counsel LLC purchased a new stake in shares of Boston Scientific during the 3rd quarter valued at approximately $204,000. Finally, Perkins Capital Management Inc. purchased a new stake in shares of Boston Scientific during the 3rd quarter valued at approximately $204,000. 90.51% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: “Boston Scientific Corporation (BSX) Given Average Recommendation of “Buy” by Analysts” was originally posted by Daily Political and is the property of of Daily Political. If you are viewing this article on another site, it was illegally copied and republished in violation of United States & international copyright laws. The correct version of this article can be read at https://www.dailypolitical.com/2018/01/19/boston-scientific-corporation-bsx-given-average-recommendation-of-buy-by-analysts.html.

About Boston Scientific

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Analyst Recommendations for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.